A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

To be considered for this study, you would generally need to have a confirmed diagnosis of certain types of aggressive B-cell non-Hodgkin's lymphoma that has returned or not responded to previous treatments. You must have had at least one prior treatment for your lymphoma. If you've only had one previous treatment, you usually wouldn't be able to join if you're a good candidate for a stem cell transplant, as that might be a more standard option for you.

Your general health also needs to be good enough to participate. This means your doctor will check your overall physical condition, and you need to have certain levels of blood cell counts and kidney function. The cancer also needs to be measurable on scans so doctors can track how it responds to the treatment. Crucially, your doctor needs to believe that you would be able to handle the initial doses of treatment in an outpatient setting, meaning you wouldn't need to stay in the hospital.

There are also some reasons why you might not be able to join. For instance, if you've previously been part of certain other specific research studies, or if you've already had glofitamab or similar drugs. Certain other medical conditions or reactions to specific medications (like obinutuzumab, gemcitabine, oxaliplatin, or tocilizumab) would also mean you couldn't participate. You also can't have had gemcitabine or oxaliplatin before this study, or have certain types of nerve damage.

If you decide to take part in this study, you would receive several different medications. These include obinutuzumab, glofitamab, gemcitabine, and oxaliplatin. Before starting the main treatment, you'll likely receive steroid medication to help prevent side effects. The study involves regular visits to the clinic for your treatments and to have your health monitored closely. The researchers will be paying special attention to a side effect called cytokine release syndrome (CRS), particularly during the initial doses of glofitamab, to ensure your safety. They will look at your blood tests and other assessments often. The aim is to deliver the early stages of treatment in an outpatient setting, meaning you'd go home after your treatment sessions rather than staying in the hospital. The total duration of your participation in the study would be determined by your response to treatment and your doctor's assessment, followed by a period of follow-up to track your long-term health.